Karen Mulholland, PA
Medical · Amsterdam, NYNPI 1275918294
Payments from drug & device makers
Across 392 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$831
- Sanofi$789
- Regeneron Healthcare Solutions, Inc.$725
- Electromed, Inc.$208
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,769100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 96 | $1,876 |
| GSK | 111 | $1,745 |
| Boehringer Ingelheim | 40 | $831 |
| Sanofi | 30 | $789 |
| Regeneron Healthcare Solutions, Inc. | 29 | $725 |
| Electromed, Inc. | 10 | $208 |
| Pulmonx Corporation | 6 | $155 |
| AbbVie | 7 | $142 |
| Grifols USA, LLC | 6 | $134 |
| Amgen | 6 | $133 |
| Insmed, Inc. | 5 | $113 |
| Actelion Pharmaceuticals US, Inc. | 4 | $104 |
| Novartis | 5 | $103 |
| Johnson & Johnson | 6 | $100 |
| Philips North America LLC | 5 | $99 |
| Verona Pharma, Inc. | 4 | $99 |
| Mylan Specialty L.p. | 5 | $90 |
| Jazz Pharmaceuticals Inc. | 4 | $74 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| Viatris Specialty LLC | 2 | $55 |
| Merck | 2 | $40 |
| Pfizer | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
How this compares
$7,778 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 264 | $274,596 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 153 | $198,206 |
| Dupixent PenDupilumab | 33 | $121,775 |
| NucalaMepolizumab | 34 | $117,452 |
| Dupixent SyringeDupilumab | 19 | $87,452 |
| Fasenra PenBenralizumab | 15 | $80,764 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $77,509 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 98 | $63,594 |
| Breo ElliptaFluticasone/Vilanterol | 74 | $43,390 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $29,411 |
| Spiriva RespimatTiotropium Bromide | 19 | $20,094 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $18,933 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 55 | $18,468 |
| Advair HfaFluticasone Propion/Salmeterol | 33 | $16,784 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $11,554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,745 | $508,524482 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,876 | $217,139192 claims |
| Grifols USA, LLCProlastin C | $134 | $77,50911 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $831 | $49,50552 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.
Other medical in Amsterdam
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.